Northwest Biotherapeutics, Inc. (NWBO)
Market Cap | 469.22M |
Revenue (ttm) | 1.34M |
Net Income (ttm) | -70.78M |
Shares Out | 1.21B |
EPS (ttm) | -0.06 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 408,904 |
Open | 0.388 |
Previous Close | 0.387 |
Day's Range | 0.385 - 0.394 |
52-Week Range | 0.378 - 1.090 |
Beta | -0.58 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Feb 28, 2023 |
About NWBO
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors.... [Read more]
Financial Performance
In 2023, NWBO's revenue was $1.93 million, an increase of 14.80% compared to the previous year's $1.68 million. Losses were -$62.60 million, -54.26% less than in 2022.
Financial StatementsNews
![](https://cdn.snapi.dev/images/v1/n/b/press11-2508878.jpg)
Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities
Over 77% Of All Shares Voted; Proposals Received Overwhelming Positive Votes BETHESDA, Md. , July 3, 2024 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company de...
![](https://cdn.snapi.dev/images/v1/l/q/press14-2482069.jpg)
Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property
Complementary to Technology & IP Already Owned or In-Licensed; Significant Step in Building a Leading Dendritic Cell Franchise BETHESDA, Md. , June 17, 2024 /PRNewswire/ -- Northwest Biotherapeutics (...
![](https://cdn.snapi.dev/images/v1/t/8/press3-2335676.jpg)
Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors
BETHESDA, Md. , March 21, 2024 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, anno...
![](https://cdn.snapi.dev/images/v1/6/i/press16-2262177.jpg)
Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification
Accompanied by Broad Patent Coverage BETHESDA, Md. , Feb. 6, 2024 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune ther...
![](https://cdn.snapi.dev/images/v1/f/v/press6-2205128.jpg)
Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma
Culmination Of Over 20 Years Of Research And Clinical Development BETHESDA, Md. , Dec. 21, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing D...
![](https://cdn.snapi.dev/images/v1/r/d/press6-2168873.jpg)
Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application
BETHESDA, Md. , Nov. 22, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, provi...
![](https://cdn.snapi.dev/images/v1/m/b/press20-2102575.jpg)
Northwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization Application
BETHESDA, Md. , Oct. 13, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, provi...
![](https://cdn.snapi.dev/images/v1/l/y/press2-2059710.jpg)
Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Board
BETHESDA, Md. , Sept. 12, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, anno...
![](https://cdn.snapi.dev/images/v1/s/u/press8-2041355.jpg)
Northwest Biotherapeutics Announces Completion of Prerequisites, and Plans for Submission of Marketing Authorization Application
BETHESDA, Md. , Aug. 29, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, annou...
![](https://cdn.snapi.dev/images/v1/9/l/press11-1805135.jpg)
Northwest Biotherapeutics and Advent BioServices Announce Receipt of License for Commercial Manufacturing at Sawston, U.K. Facility
One of the First UK Licenses for Commercial Manufacturing of Cell Therapy Products; Allows Global Delivery of the Products BETHESDA, Md., March 20, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQ...
![](https://cdn.snapi.dev/images/v1/u/r/press12-1792709.jpg)
Northwest Biotherapeutics Announces That It Has No Banking Relationship With SVB
BETHESDA, Md. , March 11, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, tod...
![](https://cdn.snapi.dev/images/v1/e/6/press5-1698396.jpg)
Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews 2022 Progress and Looks Forward to Strong 2023
78% Of All Shares Were Voted; Proposals Received ≥90% of Votes Cast BETHESDA, Md. , Jan. 6, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing ...
![](https://cdn.snapi.dev/images/v1/s/o/social-1658590.jpg)
Biotech Company Says Citadel, Other Big Traders Manipulated Its Stock Price
In a new lawsuit, Northwest Biotherapeutics accused market makers of illicit “spoofing” trades.
![](https://cdn.snapi.dev/images/v1/c/u/press18-1642400.jpg)
Northwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax®-L for Glioblastoma
Both Median Survival and "Long Tail" of Extended Survival Were Increased In Both Newly Diagnosed and Recurrent Glioblastoma Results Featured In JAMA Oncology Peer Reviewed Publication BETHESDA, Md....
![](https://cdn.snapi.dev/images/v1/u/f/press5-1515843.jpg)
Northwest Biotherapeutics Announces Approval of Pediatric Investigation Plan (PIP) by MHRA
PIP Approval Is A Pre-Requisite for Application for Approval of A New Medicine for Adult Patients BETHESDA, Md. , Aug. 23, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a bi...
![](https://cdn.snapi.dev/images/v1/g/j/press19-1442266.jpg)
Northwest Biotherapeutics Announces Filing of Application for License for Commercial Manufacturing at Sawston, UK Facility
Application Package Developed By Advent BioServices; Builds on Licenses Obtained in 2021 BETHESDA, Md. , July 6, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnolog...
![](https://cdn.snapi.dev/images/v1/0/m/press18-1403625.jpg)
Northwest Biotherapeutics Announces Presentations On DCVax®-L Personalized Vaccines, Manufacturing and Scale-Up, and DCVax®-L Clinical Program
BETHESDA, Md. , June 5, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, report...
![](https://cdn.snapi.dev/images/v1/l/q/press17-1365821.jpg)
Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma Today At New York Academy of Sciences To Be Available Online As Well
BETHESDA, Md. , May 10, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, report...
![](https://cdn.snapi.dev/images/v1/r/t/press2-1354040.jpg)
Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma To Be Made At New York Academy Of Sciences
BETHESDA, Md. , May 4, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reporte...
![](https://cdn.snapi.dev/images/v1/3/k/press15-1238768.jpg)
Northwest Biotherapeutics Announces Commencement Of Cancer Vaccine Production At Its Sawston, UK Facility
BETHESDA, Md., Feb. 17, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today ...
![](https://cdn.snapi.dev/images/v1/n/4/press9-1158784.jpg)
Northwest Biotherapeutics Announces MHRA Approval Of License for GMP Manufacturing At Sawston, UK Facility
BETHESDA, Md., Dec. 21, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today ...
![](https://cdn.snapi.dev/images/v1/8/u/press17-1126835.jpg)
Northwest Biotherapeutics Announces $15 Million Financing
BETHESDA, Md., Nov. 29, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today ...
![](https://cdn.snapi.dev/images/v1/i/m/press15-1076673.jpg)
Northwest Biotherapeutics Announces HTA License Issued and MHRA Inspection Conducted for Sawston, UK Facility
BETHESDA, Md., Oct. 28, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today ...
![](https://cdn.snapi.dev/images/v1/j/f/press5-818822.jpg)
UK Manufacturing Facility & Phase III Trial Updates From Northwest Biotherapeutics (OTCQB: NWBO)
BETHESDA, Md., May 12, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today a...
![](https://cdn.snapi.dev/images/v1/l/v/press2-725597.jpg)
Northwest Biotherapeutics Announces Development Completed for Initial Production Capacity of Sawston, UK Facility
BETHESDA, Md., March 16, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today...